<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554189</url>
  </required_header>
  <id_info>
    <org_study_id>8325-002</org_study_id>
    <secondary_id>2011-006263-22</secondary_id>
    <nct_id>NCT01554189</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C Infected Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to assess the safety, pharmacokinetics (PK) and pharmacodynamics
      (PD) of MK-8325 in male hepatitis C virus (HCV)-infected participants. There will be 3 parts
      to this study. Part I will enroll only genotype 1 (GT1) HCV patients, Part II will enroll
      only genotype 3 (GT3) HCV-infected participants, and Part III will enroll only GT1a
      HCV-infected participants. All parts may run concurrently, or may be staggered as needed by
      the clinical sites.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 5 in plasma HCV ribonucleic acid (RNA) in GT1 participants</measure>
    <time_frame>Day 1 predose and 2, 4, 8, 12, 24 and 36 hours post-dose, Days 3 and 4 predose, Day 5 predose and 2, 4, 8, 12, and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum reduction from baseline through Day 5 in HCV ribonucleic acid (RNA) in GT3 participants</measure>
    <time_frame>Day 1 predose and 2, 4, 8, 12, 24 and 36 hours post-dose, Days 3 and 4 predose, Day 5 predose and 2, 4, 8, 12, and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing at least one adverse event</measure>
    <time_frame>Day 1 up to 56 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study drug due to an adverse event</measure>
    <time_frame>Days 1-5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (C24hr) of MK-8325</measure>
    <time_frame>Day 1 predose and 0.25 0.5, 1, 2, 4, 5, 6, 7, 8, 12, 16 and 24 hours post-dose and Day 5 predose and 0.25, 0.5, 1, 2, 4, 5, 6, 7, 8, 12, 16, 24, 36,48, 72, 96, 120, 144, 168, 192, 216, and 240 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve from Hour 0 to Hour 24 (AUC0-24hr) for MK-8325</measure>
    <time_frame>Day 1 predose and 0.25 0.5, 1, 2, 4, 5, 6, 7, 8, 12, 16 and 24 hours post-dose and Day 5 predose and 0.25, 0.5, 1, 2, 4, 5, 6, 7, 8, 12, 16 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of MK-8325</measure>
    <time_frame>Day 1 predose and 0.25 0.5, 1, 2, 4, 5, 6, 7, 8, 12, 16 and 24 hours post-dose and Day 5 predose and 0.25, 0.5, 1, 2, 4, 5, 6, 7, 8, 12, 16, 24, 36,48, 72, 96, 120, 144, 168, 192, 216, and 240 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Panel A (GT1 10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B (GT1 50 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C (GT1 100 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D (GT1 200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E (GT3 10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel F (GT3 50 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel G (GT3 100 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel H (GT3 200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel I (GT1a 10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel J (GT1a 50 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Panel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8325</intervention_name>
    <description>MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)</description>
    <arm_group_label>Panel A (GT1 10 mg)</arm_group_label>
    <arm_group_label>Panel B (GT1 50 mg)</arm_group_label>
    <arm_group_label>Panel C (GT1 100 mg)</arm_group_label>
    <arm_group_label>Panel D (GT1 200 mg)</arm_group_label>
    <arm_group_label>Panel E (GT3 10 mg)</arm_group_label>
    <arm_group_label>Panel F (GT3 50 mg)</arm_group_label>
    <arm_group_label>Panel G (GT3 100 mg)</arm_group_label>
    <arm_group_label>Panel H (GT3 200 mg)</arm_group_label>
    <arm_group_label>Panel I (GT1a 10 mg)</arm_group_label>
    <arm_group_label>Panel J (GT1a 50 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match MK-8325 capsules, orally, once per day for 5 days</description>
    <arm_group_label>Placebo Panel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Body mass index (BMI) of 18 to ≤37 kg/m^2

          -  Diagnosis of chronic HCV infection

          -  Must be infected with HCV GT1a, GT1b, or GT3

        Exclusion criteria:

          -  Co-infection with GT1 and GT3 HCV

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of clinically significant endocrine, gastrointestinal (excepting HCV
             infection), cardiovascular, hematological, immunological, renal, respiratory, or
             genitourinary abnormalities or diseases

          -  History of neoplastic disease

          -  Positive Hepatitis B surface antigen

          -  History of human immunodeficiency virus (HIV) infection or positive HIV serology

          -  Major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated
             in another investigational study within 4 weeks prior

          -  History of significant multiple and/or severe allergies (including latex allergy), or
             anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Current regular user (including &quot;recreational use&quot;) of any illicit drugs or history of
             drug (including alcohol) abuse within approximately 2 months

          -  Evidence or history of chronic hepatitis not caused by HCV including but not limited
             to non-HCV viral hepatitis, non-alcoholic steatohepatitis (NASH), drug-induced
             hepatitis, autoimmune hepatitis

          -  Previous treatments(s) with nonstructural 5A (NS5A) protein inhibitors

          -  Treatment with protease inhibitor(s) &lt;30 days prior to study enrollment

          -  Previous exposure to interferon-alpha and/or ribavirin within 3 months prior to the
             first dose of MK-8325 in the study

          -  Clinical or laboratory evidence of advanced or decompensated liver disease; evidence
             of bridging fibrosis or higher grade fibrosis (Metavir score ≥3) from prior liver
             biopsy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

